{"title":"二尖瓣置换术中伴随手术消融的有效性和安全性:一项系统综述。","authors":"Omar Hamodat, Saif Almuzainy, Rand Yahya, Razan Alzaatreh, Samiullah Haroon, Salam Koniali","doi":"10.37616/2212-5043.1426","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Atrial fibrillation (AF) is a common comorbidity in patients undergoing mitral valve surgery (MVS), significantly increasing the risk of thromboembolism, heart failure, and mortality. Surgical ablation has recently been given a Class IA recommendation for concomitant MVS, reinforcing its role in restoring sinus rhythm and improving outcomes in this population. However, concerns about procedural complexity, extended operative time, and postoperative risks have limited its widespread adoption. This systematic review aims to synthesize evidence from recent randomized controlled trials to evaluate the safety and efficacy of surgical ablation for AF in patients undergoing MVS, addressing critical gaps in current clinical practice.</p><p><strong>Methodology: </strong>We systematically searched Scopus, PubMed, and Ovid up to December of 2024 for randomized controlled trials (RCTs) that investigated surgical ablation concomitant to mitral valve repair or replacement (MVR) as the intervention, compared to isolated MVR.</p><p><strong>Results: </strong>This review included 15 RCTs with 1219 patients (681 in the MVR + ablation group and 538 in the MVR-only group). Sinus rhythm restoration was significantly higher in the MVR + ablation group at discharge (64.7% vs. 18.8%), 6 months (62.5% vs. 22.4%), and 1 year (66.0% vs. 25.7%), indicating both immediate and sustained benefits. Short-term mortality rates were similar between groups (2.2% vs. 1.97%), while 1-year mortality was lower in the MVR + ablation group (5.43% vs. 5.91%). Pacemaker implantation rates were slightly higher in the MVR + ablation group, while stroke and thromboembolic events were rare and comparable between groups.</p><p><strong>Conclusion: </strong>Surgical ablation combined with mitral valve surgery significantly improves sinus rhythm outcomes. While stroke and short-term mortality remain comparable between groups, one-year mortality was lower in the ablation group, warranting further investigation. Additionally, the increased pacemaker implantation rate in specific populations warrants tailored approaches.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"37 2","pages":"4"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12017695/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Concomitant Surgical Ablation During Mitral Valve Replacement: A Systematic Review.\",\"authors\":\"Omar Hamodat, Saif Almuzainy, Rand Yahya, Razan Alzaatreh, Samiullah Haroon, Salam Koniali\",\"doi\":\"10.37616/2212-5043.1426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Atrial fibrillation (AF) is a common comorbidity in patients undergoing mitral valve surgery (MVS), significantly increasing the risk of thromboembolism, heart failure, and mortality. Surgical ablation has recently been given a Class IA recommendation for concomitant MVS, reinforcing its role in restoring sinus rhythm and improving outcomes in this population. However, concerns about procedural complexity, extended operative time, and postoperative risks have limited its widespread adoption. This systematic review aims to synthesize evidence from recent randomized controlled trials to evaluate the safety and efficacy of surgical ablation for AF in patients undergoing MVS, addressing critical gaps in current clinical practice.</p><p><strong>Methodology: </strong>We systematically searched Scopus, PubMed, and Ovid up to December of 2024 for randomized controlled trials (RCTs) that investigated surgical ablation concomitant to mitral valve repair or replacement (MVR) as the intervention, compared to isolated MVR.</p><p><strong>Results: </strong>This review included 15 RCTs with 1219 patients (681 in the MVR + ablation group and 538 in the MVR-only group). Sinus rhythm restoration was significantly higher in the MVR + ablation group at discharge (64.7% vs. 18.8%), 6 months (62.5% vs. 22.4%), and 1 year (66.0% vs. 25.7%), indicating both immediate and sustained benefits. Short-term mortality rates were similar between groups (2.2% vs. 1.97%), while 1-year mortality was lower in the MVR + ablation group (5.43% vs. 5.91%). Pacemaker implantation rates were slightly higher in the MVR + ablation group, while stroke and thromboembolic events were rare and comparable between groups.</p><p><strong>Conclusion: </strong>Surgical ablation combined with mitral valve surgery significantly improves sinus rhythm outcomes. While stroke and short-term mortality remain comparable between groups, one-year mortality was lower in the ablation group, warranting further investigation. Additionally, the increased pacemaker implantation rate in specific populations warrants tailored approaches.</p>\",\"PeriodicalId\":17319,\"journal\":{\"name\":\"Journal of the Saudi Heart Association\",\"volume\":\"37 2\",\"pages\":\"4\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12017695/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Saudi Heart Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37616/2212-5043.1426\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Saudi Heart Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37616/2212-5043.1426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:房颤(AF)是二尖瓣手术(MVS)患者的常见合并症,显著增加血栓栓塞、心力衰竭和死亡率的风险。手术消融最近被推荐为治疗合并MVS的a类推荐,强化了其在恢复窦性心律和改善该人群预后方面的作用。然而,对手术复杂性、延长手术时间和术后风险的担忧限制了其广泛采用。本系统综述旨在综合近期随机对照试验的证据,以评估手术消融治疗MVS患者房颤的安全性和有效性,解决当前临床实践中的关键空白。方法:我们系统地检索了Scopus、PubMed和Ovid截至2024年12月的随机对照试验(RCTs),这些试验研究了手术消融合并二尖瓣修复或置换术(MVR)作为干预措施,并与孤立的MVR进行了比较。结果:本综述纳入15项随机对照试验,共1219例患者(MVR +消融组681例,仅MVR组538例)。MVR +消融组在出院时(64.7% vs. 18.8%)、6个月(62.5% vs. 22.4%)和1年(66.0% vs. 25.7%)窦性心律恢复明显更高,显示了即时和持续的益处。两组间短期死亡率相似(2.2% vs. 1.97%), MVR +消融组1年死亡率较低(5.43% vs. 5.91%)。MVR +消融组的起搏器植入率略高,而卒中和血栓栓塞事件罕见,两组之间具有可比性。结论:外科消融联合二尖瓣手术可显著改善窦性心律。虽然两组间卒中和短期死亡率保持可比性,但消融术组一年死亡率较低,值得进一步研究。此外,在特定人群中增加的起搏器植入率需要量身定制的方法。
Efficacy and Safety of Concomitant Surgical Ablation During Mitral Valve Replacement: A Systematic Review.
Objectives: Atrial fibrillation (AF) is a common comorbidity in patients undergoing mitral valve surgery (MVS), significantly increasing the risk of thromboembolism, heart failure, and mortality. Surgical ablation has recently been given a Class IA recommendation for concomitant MVS, reinforcing its role in restoring sinus rhythm and improving outcomes in this population. However, concerns about procedural complexity, extended operative time, and postoperative risks have limited its widespread adoption. This systematic review aims to synthesize evidence from recent randomized controlled trials to evaluate the safety and efficacy of surgical ablation for AF in patients undergoing MVS, addressing critical gaps in current clinical practice.
Methodology: We systematically searched Scopus, PubMed, and Ovid up to December of 2024 for randomized controlled trials (RCTs) that investigated surgical ablation concomitant to mitral valve repair or replacement (MVR) as the intervention, compared to isolated MVR.
Results: This review included 15 RCTs with 1219 patients (681 in the MVR + ablation group and 538 in the MVR-only group). Sinus rhythm restoration was significantly higher in the MVR + ablation group at discharge (64.7% vs. 18.8%), 6 months (62.5% vs. 22.4%), and 1 year (66.0% vs. 25.7%), indicating both immediate and sustained benefits. Short-term mortality rates were similar between groups (2.2% vs. 1.97%), while 1-year mortality was lower in the MVR + ablation group (5.43% vs. 5.91%). Pacemaker implantation rates were slightly higher in the MVR + ablation group, while stroke and thromboembolic events were rare and comparable between groups.
Conclusion: Surgical ablation combined with mitral valve surgery significantly improves sinus rhythm outcomes. While stroke and short-term mortality remain comparable between groups, one-year mortality was lower in the ablation group, warranting further investigation. Additionally, the increased pacemaker implantation rate in specific populations warrants tailored approaches.